Skip to main content
Erschienen in: Digestive Diseases and Sciences 2/2016

01.02.2016 | Editorial

Bin1 Antibodies for IBD Therapy: Is Permeability the Answer BAR None?

verfasst von: George Kolios

Erschienen in: Digestive Diseases and Sciences | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Excerpt

The inflammatory bowel diseases (IBD) ulcerative colitis (UC) and Crohn’s disease (CD), of unknown etiology despite being extensively investigated over the last few decades, share important common pathogenic mechanisms. The interaction of genetic predisposing factors, exogenous and endogenous triggers, and modifying mediators induce inflammation and immune-mediated tissue injury. In UC, with inflammation mostly limited to the large bowel, acute and chronic inflammatory cells infiltrate the lamina propria with the formation of crypt microabscesses [1]. Recent diagnostic and therapeutic advances have been based on the increasing knowledge of the interplay between the cellular components and soluble mediators in the gut mucosa, combined with therapeutic strategies that target immunological mechanisms [2]. …
Literatur
2.
Zurück zum Zitat Cohen LB, Nanau RM, Delzor F, Neuman MG. Biologic therapies in inflammatory bowel disease. Transl Res. 2014;163:533–556.CrossRefPubMed Cohen LB, Nanau RM, Delzor F, Neuman MG. Biologic therapies in inflammatory bowel disease. Transl Res. 2014;163:533–556.CrossRefPubMed
3.
Zurück zum Zitat Bernstein CN. Treatment of IBD: where we are and where we are going. Am J Gastroenterol. 2015;110:114–126.CrossRefPubMed Bernstein CN. Treatment of IBD: where we are and where we are going. Am J Gastroenterol. 2015;110:114–126.CrossRefPubMed
4.
Zurück zum Zitat Mankertz J, Schulzke JD. Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications. Curr Opin Gastroenterol. 2007;23:379–383.CrossRefPubMed Mankertz J, Schulzke JD. Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications. Curr Opin Gastroenterol. 2007;23:379–383.CrossRefPubMed
5.
Zurück zum Zitat Thomas S, Mercado JM, DuHadaway J, DiGuilio K, Mullin JM, Prendergast GC. Novel colitis immunotherapy targets Bin1 and improves colon cell barrier function. Dig Dis Sci. (Epub ahead of print). doi:10.1007/s10620-015-3804-8. Thomas S, Mercado JM, DuHadaway J, DiGuilio K, Mullin JM, Prendergast GC. Novel colitis immunotherapy targets Bin1 and improves colon cell barrier function. Dig Dis Sci. (Epub ahead of print). doi:10.​1007/​s10620-015-3804-8.
6.
Zurück zum Zitat Chang MY, Boulden J, Valenzano MC, et al. Bin1 attenuation suppresses experimental colitis by enforcing intestinal barrier function. Dig Dis Sci. 2012;57:1813–1821.PubMedCentralCrossRefPubMed Chang MY, Boulden J, Valenzano MC, et al. Bin1 attenuation suppresses experimental colitis by enforcing intestinal barrier function. Dig Dis Sci. 2012;57:1813–1821.PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Prokic I, Cowling BS, Laporte J. Amphiphysin 2 (BIN1) in physiology and diseases. J Mol Med (Berl). 2014;92:453–463.CrossRef Prokic I, Cowling BS, Laporte J. Amphiphysin 2 (BIN1) in physiology and diseases. J Mol Med (Berl). 2014;92:453–463.CrossRef
8.
Zurück zum Zitat Lundgaard GL, Daniels NE, Pyndiah S, et al. Identification of a novel effector domain of BIN1 for cancer suppression. J Cell Biochem. 2011;112:2992–3001.PubMedCentralCrossRefPubMed Lundgaard GL, Daniels NE, Pyndiah S, et al. Identification of a novel effector domain of BIN1 for cancer suppression. J Cell Biochem. 2011;112:2992–3001.PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Chang MY, Boulden J, Katz JB, et al. Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. Cancer Res. 2007;67:7605–7612.CrossRefPubMed Chang MY, Boulden J, Katz JB, et al. Bin1 ablation increases susceptibility to cancer during aging, particularly lung cancer. Cancer Res. 2007;67:7605–7612.CrossRefPubMed
10.
Zurück zum Zitat Jia Y, Wang H, Wang Y, et al. Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients. Int J Cancer. 2015;137:1095–1106.CrossRefPubMed Jia Y, Wang H, Wang Y, et al. Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients. Int J Cancer. 2015;137:1095–1106.CrossRefPubMed
11.
Zurück zum Zitat Valatas V, Vakas M, Kolios G. The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases. Am J Physiol Gastrointest Liver Physiol. 2013;305:G763–G785.CrossRefPubMed Valatas V, Vakas M, Kolios G. The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases. Am J Physiol Gastrointest Liver Physiol. 2013;305:G763–G785.CrossRefPubMed
Metadaten
Titel
Bin1 Antibodies for IBD Therapy: Is Permeability the Answer BAR None?
verfasst von
George Kolios
Publikationsdatum
01.02.2016
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 2/2016
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-015-3997-x

Weitere Artikel der Ausgabe 2/2016

Digestive Diseases and Sciences 2/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.